Novel anti-viral agents to treat influenza

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$3,000,000.00
Award Year:
2013
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI084244-03A1
Agency Tracking Number:
R44AI084244
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
ALEXANDER BIODISCOVERIES, LLC
530 FORREST RD, CHARLOTTESVILLE, VA, 22902-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
828800040
Principal Investigator:
DIPANWITA BASU
(434) 825-5210
AlexanderBioDiscoveries@gmail.com
Business Contact:
DANIEL ENGEL
(434) 825-5210
AlexanderBioDiscoveries@gmail.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the UnitedStates. In addition, the likelihood of a severe pandemic caused by a newly emergent strain of influenza virus is very high, given that three such pandemics were recorded in the 20th century, plus the swine H1N1 pandemic of 2009. The most devastating of these, the 1918 Spanish influenza, was associated with an estimated 40 million deaths worldwide. The annual vaccine for seasonal influenza is only partially effective in prevention of disease. Likewise, currently available anti-influenza drugs such as amantadine and oseltamivir are only partially effective in treatment prophylaxis, and also suffer from problems of drug resistance. Therefore, there is an urgent need for additional anti-influenza therapeutics that target unexploited aspects of viral biology. The proposed studies are directed at developing new drugs that can combat influenza virus. The viral NS1 protein is an attractive drug target because it is essential for virus replication in vivo. Small molecules that inhibit NS1 function are expected to block virus replication, and hence disease. During Phase I, two chemical series were developed that specifically inhibit NS1 function during infection. These compounds inhibit virus replication in cell culture and an animal model. The goal for Phase II is to develop these series to be ready for IND-enabling pharmacology and toxicology in Phase III. In Aim 1, medicinal chemistry approaches will be used to create highly potent, non-toxic analogs. In Aim 2, purified NS1 protein will be used in biochemical assays to determine binding constants for the newly synthesized analogs, and X-ray crystallography will be employed to understand the structure of ligand-drug complexes. These methods will support the design of better NS1 inhibitors. In Aim 3, the analogs willbe assessed according to several criteria including antiviral activity, cytotoxicity, induction of cellular interferon, and in vitro ADME properties. Aim 4 will culminate with in vivo testing in BALB/c mice, including MTD, PK and efficacy studies.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizationsin the United States. The proposed research is directed at developing new drugs that can combat influenza virus, the virus that causes influenza.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government